Adjuvant clinical trials

Explore recruiting adjuvant clinical trials.

Recruiting adjuvant studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Adjuvant trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Pancreatic head resection or total pancreatectomy with islet autotransplantation (IATx) in patients with periampullary cancer and high risk profile for the development of postoperative pancreatic fistula (POPF) - XandTX Trial

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study.

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

OPTPEMBRO : OPTimizing adjuvant prescription of PEMBROlizumab in patients with early-stage triple-negative breast cancer achieving pathologic complete response after standard neoadjuvant chemotherapy and pembrolizumab

France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

PembroLizumab Adjuvant in patients with early-stage Triple NEgaTive breast cancer with residual disease after neoadjuvant pembrolizumab plus chemotherapy – the multicenter, randomized phase III, pragmatic PLANET trial

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Adjuvant trials by city

Adjuvant in Toronto Adjuvant in Vancouver Adjuvant in Montreal Adjuvant in Calgary Adjuvant in Edmonton Adjuvant in Ottawa Adjuvant in Winnipeg Adjuvant in Quebec City Adjuvant in Hamilton Adjuvant in Kitchener Adjuvant in London Adjuvant in Halifax Adjuvant in New York Adjuvant in Los Angeles Adjuvant in Chicago Adjuvant in Houston

Adjuvant clinical trials

Recruiting adjuvant studies right now

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Exercise During Chemotherapy Treatment As Adjuvant Program in Patients with Lymphoma: EDONOLA Study.

Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer

JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

Also recruiting in Europe

Pancreatic head resection or total pancreatectomy with islet autotransplantation (IATx) in patients with periampullary cancer and high risk profile for the development of postoperative pancreatic fistula (POPF) - XandTX Trial

Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study.

OPTPEMBRO : OPTimizing adjuvant prescription of PEMBROlizumab in patients with early-stage triple-negative breast cancer achieving pathologic complete response after standard neoadjuvant chemotherapy and pembrolizumab

PembroLizumab Adjuvant in patients with early-stage Triple NEgaTive breast cancer with residual disease after neoadjuvant pembrolizumab plus chemotherapy – the multicenter, randomized phase III, pragmatic PLANET trial

The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer

PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II

Adjuvant trials by city

Other conditions